产品展示
中英文说明丨艾美捷InVivoMAb 抗小鼠NK1.1
点击次数:0发布时间:2023/3/30 16:49:24
更新日期:2023/3/30 16:49:24
所 在 地:中国大陆
产品型号:
优质供应
详细内容
Isotype Mouse IgG2a, κ
Recommended Isotype Control(s) InVivoMAb mouse IgG2a isotype control, unknown specificity
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Immunogen Mouse spleen and bone marrow cells enriched for NK1+ cells
Reported Applications in vivo NK cell depletion
Flow cytometry
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <2EU/mg (<0.002EU/μg)
Determined by LAL gel clotting assay
Purity >95%
Determined by SDS-PAGE
Sterility 0.2 μM filtered
Production Purified from tissue culture supernatant in an animal free facility
Purification Protein A
RRID AB_1107737
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
PK136单克隆抗体与小鼠NK1.1反应,也称为CD161b / CD161c,KLRB1,NKR-P1A和Ly-55。NK1.1是一种具有C型凝集素结构域的II型整合膜糖蛋白,由Klrb1c/NKR-P1C基因编码。NK1.1在NK细胞活化和分化,IFN-γ产生,细胞毒性颗粒释放中起作用,并被认为参与Th2细胞的产生。NK1.1主要在NK细胞上表达为二硫键连接的同源二聚体,然而,它也在NK-T细胞上表达,NK-T细胞是一种罕见的T淋巴细胞群。NK 1.1仅由小鼠的C57BL / 6,FVB / N和NZB菌株表达,而不是AKR,BALB / c,CBA / J,C3H,DBA / 1,DBA / 2,NOD,SJL和129株表达。
艾美捷InVivoMAb抗小鼠NK1.1#BE0036基本参数:
同种型 小鼠IgG2a, κ
推荐的同种型对照 体内MAb小鼠IgG2a同种型对照,特异性未知
推荐的稀释缓冲液 体内纯 pH 7.0 稀释缓冲液
免疫原 富含NK1+细胞的小鼠脾脏和骨髓细胞
报告的应用程序 体内NK细胞去除
流式细胞术
配方 PBS,pH 7.0
不含稳定剂或防腐剂
内毒素 <2EU/mg (<0.002EU/μg)
通过LAL凝胶凝血测定法测定
纯度 >95%
由 SDS-PAGE 决定
无 菌 0.2 μM 过滤
生产 从无动物设施中的组织培养上清液中纯化
纯化 蛋白A
里德 AB_1107737
分子量 150 千达
存储 抗体溶液应以4°C的储备浓度储存。 不要冻结。
InVivoMAb抗小鼠NK1.1部分文献引用:
in vivo NK cell depletion
Ghasemi, R., et al. (2016). "Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy" Nat Commun 7: 12878.
in vivo NK cell depletion, Flow Cytometry
Maltez, V. I., et al. (2015). "Inflammasomes Coordinate Pyroptosis and Natural Killer Cell Cytotoxicity to Clear Infection by a Ubiquitous Environmental Bacterium" Immunity 43(5): 987-997.
in vivo NK cell depletion, Flow Cytometry
Wensveen, F. M., et al. (2015). "NK cells link obesity-induced adipose stress to inflammation and insulin resistance" Nat Immunol 16(4): 376-385.
in vivo NK cell depletion
Yamada, D. H., et al. (2015). "Suppression of Fcgamma-receptor-mediated antibody effector function during persistent viral infection" Immunity 42(2): 379-390.